News
Ask a Fool: Why Do Drugmakers Do Interim Clinical Trials?
The cost of clinical trials jumps significantly when drugmakers move from phase 1 to phase 2 and phase 2 to phase 3. To reduce research and development costs, drugmakers are increasingly embracing....
Expect Higher Dividends Before 2017 Ends From These 3 Stocks
Many of the best dividend stocks in the market have impressive track records of growing their payouts over time. A select few have even gotten to the point at which investors can predict exactly....
3 Reasons to Buy the Dip With Exelixis
In just two days, Exelixis (NASDAQ: EXEL) has lost over 15% of its market cap. The tumble for the once-hot biotech stock started last week with a downgrade of the stock by an analyst at Leerink....
How Safe Is Brown-Forman's Dividend?
Dividend investors like reliable businesses, and the alcohol and spirits industry has been a reliable producer of profits for centuries. Brown-Forman (NYSE: BF-A) (NYSE: BF-B) isn't a household....
Experts Are Watching This Number at Enbridge Inc
Enbridge Inc (NYSE: ENB) is a Canadian oil and gas midstream giant that sports an impressive 4.6% yield -- well more than twice what the broader market is offering investors today. It has big....
Caveat Emptor When Buying High-Yield Drug Stocks
Income investors seemingly have hundreds of stocks to choose from that currently pay a dividend. The telecom and utility sectors often generate some of the most robust payouts for investors, with....
3 High Dividend Yields That Are Here to Stay
The oil and natural gas midstream industry is filled with high yields. But not all high yields are created equal, as the 40% distribution cut at Enbridge Energy Partners in 2017 and the 75%....
Just How Rich Is Mark Cuban?
Mark Cuban is well-known for his tenure on Shark Tank. With a net worth of several billion dollars, he is by far the wealthiest of the "shark" investors. Cuban made his fortune during the dot-com....
Intel's New Desktop Processor Is No Threat to NVIDIA
On Monday, Intel Corporation (NASDAQ: INTC) raised eyebrows across the tech world by unveiling its new 8th Gen Intel Core desktop processor family. Perhaps most notably, the central processing....
How Low Does Valeant Pharmaceuticals' Debt Really Need to Go?
There's as much of a chance that Valeant Pharmaceuticals (NYSE: VRX) wipes out its debt of nearly $28.5 billion anytime soon as there is of Donald Trump receiving a birthday present from football....
Has Anheuser-Busch Finally Had Its Fill of Craft Beer?
Too much of a good thing can be, well, too much. Anheuser-Busch InBev (NYSE: BUD) has been chugging down so many pint-sized craft breweries that it is giving itself a bad hangover from the binge,....
Total Continues Its Look Beyond Fossil Fuels to Renewable Energy
No oil major has done more to build a renewable energy business than Total (NYSE: TOT). It owns two-thirds of solar manufacturer SunPower (NASDAQ: SPWR), bought battery maker Saft last year for....
PQ Group Holdings IPO: What Investors Need to Know
Is the second time the charm? PQ Group Holdings, a sprawling company that produces a wide range of inorganic chemicals, undoubtedly hopes so. It's about to launch an IPO, not long after it....
5 Numbers That Should Get MannKind Investors Excited
MannKind (NASDAQ: MNKD) hasn't exactly given investors a whole lot to get excited about in recent years. That could be changing, though. Since May, MannKind stock has soared more than 130% and now....
3 Bargain Biotech Stocks You Can Buy Today
You might have heard that the stock market is overpriced after years of solid gains. And it is. That doesn't mean every stock is overpriced, though.Actually, several biotech stocks look....
3 Reasons Ciena Corporation Is Staying Ahead of the Competition
In researching my latest article on Ciena's (NYSE: CIEN) recent quarter, I found a lot to like about the company. As Foolish investors, we are always on the lookout for companies with outstanding....
What the IRS Should Do Now to Protect Taxpayers From Fraud
The recent data breach at Equifax is just the latest reminder of the threat that identity theft poses. Although most people are aware of the possibility of having their credit cards used....
4 Signs You Might Never Retire
Countless Americans look forward to retirement and the flexible lifestyle it tends to offer. Unfortunately, a large number of workers might never get there. In a TD Ameritrade study, 25% of U.S.....
Why Retiring Rich Is Harder Than You May Think
It's more important than ever for working-age Americans to prepare for retirement on their own. Yet as simple as it sounds to be able to retire rich, the reality is a lot tougher for most people.....
3 Value Stocks to Hold for a Decade
Long ago, Ben Graham taught me that "Price is what you pay; value is what you get." Whether we're talking about socks or stocks, I like buying quality merchandise when it is marked down.-- Warren....
Taco Bell Sets Its Sights on Urban Areas
Yum! Brands (NYSE: YUM) Taco Bell plans to expand its city-based "Cantina" concept, opening 300 to 350 more locations of the higher-end eatery by 2022.These locations, which serve alcohol and....
7 of the Most Pervasive Credit Card Myths
Image source: Getty Images.There are more than a billion credit cards in existence, and the average American holds three or more. Our society is very reliant on credit cards for their convenience,....
MEDICREA s'associe à un chirurgien orthopédiste dans le cadre de la première chirurgie mondiale intégralement personnalisée de la colonne vertébrale
Medicrea s'associe à un chirurgien orthopédiste dans le cadre de la première chirurgie mondiale intégralement personnalisée de la colonne vertébrale
Lyon et New York, le 26 septembre 2017 -....
OCEASOFT : Le Cobalt ML3 d'OCEASOFT révolutionne la surveillance de la température des produits sensibles en phase de transport
MONTPELLIER - France, 26 Septembre 2017 – OCEASOFT met les réseaux de communication de demain au service du transport des produits thermosensibles avec le nouvel enregistreur mobile de....
Finisar Management Hopes to Buy More Time
Finisar (NASDAQ: FNSR) failed to live up to expectations when it released its fiscal first-quarter results on Sept. 8. Finisar's revenue guidance fell way short of Wall Street's estimates of....